July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Lack of synergistic protection by elovanoids (ELVs) and neuroprotectin D1 (NPD1) against uncompensated oxidative-stress (UOS) in human retinal pigment epithelial cells (RPE).
Author Affiliations & Notes
  • Sebastian Guido Barreiro
    FUNDAMED, Buenos Aires, CABA, Argentina
  • Pranab K Mukherjee
    Neuroscience Center of Excellence, School of medicine LSU Health, New Orleans, Louisiana, United States
  • Nicolas G Bazan
    Neuroscience Center of Excellence, School of medicine LSU Health, New Orleans, Louisiana, United States
  • Footnotes
    Commercial Relationships   Sebastian Barreiro, None; Pranab Mukherjee, None; Nicolas Bazan, Elovanoid PCT# PCT/US16/21429, publication # WO2016/144995 (C), Elovanoid PCT# PCT/US16/21429, publication # WO2016/144995 (P)
  • Footnotes
    Support  Supported by NEI EY005121 and the Eye, Ear, Nose and Throat Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3988. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sebastian Guido Barreiro, Pranab K Mukherjee, Nicolas G Bazan; Lack of synergistic protection by elovanoids (ELVs) and neuroprotectin D1 (NPD1) against uncompensated oxidative-stress (UOS) in human retinal pigment epithelial cells (RPE).. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3988.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The bioactivity of the novel derivatives of VLC-PUFAs n-3, ELVs, (Bhattacharjee S, et al. Sci Adv. 2017; Jun B, et al. Sci Rep. 2017) was compared with NPD1 to discern if they are additive or synergistic as protectors of RPE cells against uncompensated oxidative-stress (UOS) in human RPE cells. Moreover IL-1β transcription induction of COX-2 was also assessed.

Methods : 72h grown human primary RPE cultures were serum starved for 8h, stress by H2O2 (600µM) plus TNF- α (10ng/ml), and then challenged with 200nM of ELVs (32:6 and 34:6 Me) and NPD1(100) or together (ELVs 200nM and 30nM NPD1) for 16h. Apoptotic cell death was assessed by Hoechst staining using a Zeiss LSM 510 confocal microscope. Human RPE cells grown in 6-well plates were transfected with 5μg of a human COX-2–promoter (830bp) linked to luciferase as reporter gene by FUGENE 6. Four hours later, fresh medium was added, and the cells were further incubated for 8h at 37°C. Transfected cells were serum-starved for 4h and treated with IL-1β (10ng/ml) challenged with or without added ELVs or NPD1 for 8h. Cell homogenates were made, protein concentrations were adjusted, and luciferase assays were performed.

Results : UOS cause 80-90% apoptosis. Interestingly, ELVs (200nM) or NPD1 (100nM) attenuated UOS mediated apoptosis (45-50%). This bioactivity was additive when UOS stressed RPE was challenged with 200nM ELVs plus 30nM NPD1. Also we found that IL-1β mediated upregulation of luciferase activity is inhibited by ELVs or NPD1. This result also supports the notion that ELVs (200nM) and NPD1 (30nM) mediated cell signaling is additive but not synergistic.

Conclusions : ELVs inhibition of COX-2 transcriptional upregulation induced by IL-1β in human RPE uncovers this event as part of the inflammatory targeting of the novel mediators in their cyto-protective bioactivity. The ELVs- and NPD1- mediated cyto-protective additive effect suggest that the two lipid mediators follow different pathways in modulating inflammatory and RPE cell survival consequences after UOS. It is possible that they might work in a concerted manner under certain circumstances. UOS conditions likely recapitulate homeostatic disruptions in early stages and progression of age-related macular degeneration.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×